Immediate Impact
57 standout
Citing Papers
Targeting the Warburg Effect in Cancer: Where Do We Stand?
2024 Standout
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
2024 Standout
Works of Bo Lan being referenced
Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210), a novel anti‐PD‐1 antibody
2019
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Bo Lan | 598 | 314 | 153 | 169 | 49 | 880 | |
| Yeu‐Tsu N. Lee | 609 | 338 | 175 | 155 | 56 | 1.0k | |
| Xuelian Chen | 455 | 205 | 160 | 211 | 35 | 759 | |
| Vito Amoroso | 695 | 335 | 251 | 149 | 70 | 1.1k | |
| Adrian Langleben | 703 | 402 | 153 | 309 | 54 | 1.1k | |
| Fuxing Zhao | 505 | 332 | 143 | 237 | 52 | 879 | |
| Guoshuang Shen | 504 | 344 | 213 | 292 | 57 | 945 | |
| Antonio Febbraro | 636 | 310 | 239 | 245 | 56 | 1.2k | |
| Preston D. Steen | 567 | 321 | 128 | 255 | 47 | 1.0k | |
| Armando Orlandi | 494 | 232 | 235 | 184 | 85 | 831 | |
| Dengfeng Ren | 500 | 332 | 141 | 175 | 43 | 773 |
All Works
Login with ORCID to disown or claim papers
Loading papers...